KYTH Profile
Kythera Biopharmaceuticals, Inc. (KYTH) was a biopharmaceutical company that focused on developing and commercializing prescription products for the aesthetic medicine market. Its most significant product was Kybella, an injectable medication used to reduce submental fat, or "double chin," which was approved by the U.S. Food and Drug Administration (FDA) in 2015.
Kythera was acquired by Allergan plc in 2015 for approximately $2.1 billion. The acquisition allowed Allergan to expand its portfolio of medical aesthetics products, which included Botox and Juvederm.
Prior to the acquisition, Kythera had a number of clinical development programs underway for other aesthetic medicine products. These included ATX-101 for the reduction of moderate-to-severe submental fat in men, and ATX-101 for the treatment of axillary hyperhidrosis, a condition characterized by excessive underarm sweating. However, it is unclear whether Allergan has continued development of these programs after the acquisition.
Kythera was founded in 2005 and was headquartered in Westlake Village, California. The company was publicly traded on the NASDAQ stock exchange under the ticker symbol KYTH.
|
